HealthEquity (HQY) Q3 2026 earnings review
Margin Expansion Drives Beat & Raise as Fraud Costs Subside
HealthEquity delivered a strong Q3, beating bottom-line estimates and raising full-year guidance. Non-GAAP EPS grew an impressive 29% YoY, driven by significant margin expansion, with Adjusted EBITDA margins reaching 44% vs. 39% a year ago. Revenue growth was modest at 7%, decelerating for the third consecutive quarter. The most significant development was the successful containment of fraud-related costs, which fell to just $300,000 from millions in prior quarters, removing a major overhang. The company is leveraging AI for efficiency, de-risking its interest-sensitive custodial income, and aggressively returning capital to shareholders with a $94M buyback.
🐂 Bull Case
The company demonstrated significant operating leverage, expanding Adjusted EBITDA margins by 460 basis points YoY. Non-GAAP EPS growth is accelerating, proving the business can drive profitability even with moderating top-line growth.
Management successfully reduced fraud-related service costs to a negligible $300,000, down from multi-million dollar impacts in previous quarters. This removes a key investor concern and validates their investment in security.
🐻 Bear Case
YoY revenue growth has slowed for the third straight quarter, from 15% in Q1 to 7% in Q3. This trend suggests the core business is maturing, increasing reliance on margin expansion to drive earnings growth.
The Service Revenue segment, which should reflect the strength of the company's technology platform, grew less than 1% YoY. This indicates that new initiatives like the marketplace are not yet contributing materially.
⚖️ Verdict: 🟢
Bullish. The successful containment of fraud costs is a major victory that restores credibility and removes a significant drag on margins. The impressive, accelerating bottom-line growth and margin expansion story is more compelling than the modest deceleration in revenue. With guidance raised and capital returns ongoing, the operational execution is strong.
Key Themes
Margin Expansion Fueled by AI and Efficiency
HealthEquity achieved a record 71% gross margin and a 44% Adjusted EBITDA margin, a significant improvement from 39% a year ago. Management credited investments in AI for expedited claims processing and service automation as key drivers. In Q1, the company incurred $3M in fraud costs, which dropped to just $300k this quarter, directly boosting profitability. This demonstrates a successful pivot to a more efficient operating model.
Custodial Revenue Remains the Growth Engine
Custodial revenue grew 13% YoY to $159.1 million, accounting for nearly all of the company's growth. The annualized yield on HSA cash was a healthy 3.53%. To protect this crucial income stream from interest rate volatility, the company has proactively entered into $2.3 billion of Treasury bond forward contracts, locking in a blended rate of 3.94% for contracts maturing through August 2027.
New Market Opportunity via ACA Bronze Plan Legislation
Management continues to highlight the significant expansion of its addressable market from recent legislation making ACA Bronze and Catastrophic health plans HSA-eligible. They launched a new direct HSA enrollment platform to capture this retail opportunity, which they view as a 'marathon, not a sprint' but a key long-term growth driver.
Decelerating Top-Line Growth
Total revenue growth has steadily declined from 15.0% in Q1 to 8.6% in Q2 and now 7.2% in Q3. While profitability is accelerating, the slowing top line suggests the core market may be maturing, placing more pressure on new initiatives like the ACA expansion and marketplace to re-accelerate growth.
Service Revenue Stagnation Contradicts Tech Narrative
Despite management's emphasis on a tech-forward strategy with AI and a marketplace, the Service Revenue segment grew just 0.9% to $120.3 million. This lagging performance indicates that new technology-driven services and marketplace offerings are not yet generating material revenue, or are being offset by pressure in other service lines. This data point is a clear contradiction to the positive narrative around platform innovation.
Aggressive Capital Returns Continue
HealthEquity repurchased 1.0 million shares for $93.7 million in Q3, demonstrating confidence in its cash flow and valuation. The company has $258.8 million remaining on its authorization, signaling that returning capital to shareholders remains a key priority alongside debt paydown.
Other KPIs
Stable. Total HSA Assets grew 15% YoY. The mix continues to shift toward higher-growth investments, which grew 29% YoY to $17.5 billion, while HSA cash grew a modest 3% to $16.9 billion. This trend is positive for long-term member wealth but results in slower growth of the custodial cash balances that drive high-margin revenue.
Strong cash generation, up 28% from $264.1 million in the same period last year. This robust cash flow easily funded $38.7 million in capital investments and over $200 million in share repurchases during the first nine months of the year, underscoring the business's financial health.
Guidance
Management raised its full-year outlook. Revenue guidance was tightened and raised to $1.302B - $1.312B (from $1.290B - $1.310B). More significantly, the Adjusted EBITDA forecast was lifted to $555M - $565M (from $540M - $560M), reflecting confidence in sustained margin strength.
Decelerating Revenue, Accelerating Profit. The guidance midpoint implies Q4 revenue growth will decelerate to ~5% YoY. However, it also implies Q4 Adjusted EBITDA will grow ~18% YoY. This confirms the core thesis for the remainder of the year: the company will continue to prioritize and deliver profitability over top-line growth.